Name: mechanical and controlled prp injections in patients affected by androgenetic alopecia
Uploaded: 2018-01-27T14:00:00.000+00:00
Duration: 3 min 22 s
Description: Watch this Scientific Journal Video about Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia at JoVE.com

저자 아무 승인 있다.

헬싱키의 선언, 연구 프로토콜을 준수 하 고 모든 환자는 연구에 참여 하기 전에 서 면된 동의 제공.
1. 비-활성화 A-PRP 준비
<ol><li>주변 정 맥 튜브를 사용 하 여 로컬 혈액 컬렉션 프로토콜에 따라 나비 바늘으로 팔에서 혈액 헌 혈의 55 mL 수확.</li>
	<li>항 응고 제로 혈액 튜브를 산 시트르산 포도 당 (ACD) 솔루션 (시트르산의 112 m m)의 7 mL를 추가 합니다.</li>
	<li>원심 분리기는 혈액 10 분 260 x g에서 튜브에 수집. 참고: A-PRP + 헌 혈소판 가난한 플라스마 (A-PPP)의 23 mL 및 적혈구 현 탁 액 (Rbc)의 20 mL 생산 되었다.</li>
	<li>A-PRP + A PPP와 Rbc는 원심 분리기에서 포함 된 튜브를 꺼내와 레이저 광 선택기 장치에 삽입.</li>
	<li>별도 A-PRP + A-PPP 기계 흡입 키트 배치 됩니다 레이저 선택기에 의해 수행에 의해 살 균 가방. Rbc는 기계적인 흡입에 의해 자동으로 제거 됩니다. 참고: A PPP의 14 mL 수동으로 수확 이었고 키트에서 멸 균 봉투에 의해 제거. A-PRP의 9 mL 얻은 했다.</li>
</ol>2. 비-활성화 A-PRP 주사
<ol><li>AGA 정면, 정수 리, 정점, 및 후 두 영역에는 영향을 받는 환자의 두 피를 나눕니다. 주의: 마 취 (로컬 또는 조직)를 수행 하지 마십시오.</li>
	<li>Interfollicular A-PRP 주사 (0.20 mL x cm2) 의료 인젝터에 의해 수행 ( 재료의 표참조) 두 피의 선택 된 분야에 총.<ol>
<li>환자에서 탈모 정면 그리고 정수 리 지역에 지역화, 정면 지역에 독점적으로 A-PRP 주사를 수행 하 고 정수 리 영역에 위약으로 식 염 수를 사용 합니다.</li>
		<li>환자에서 탈모는 정수 리와 정점 지역 지역화, A-정수 리 영역에서 PRP를 주사 하 고 정점 영역에 위약으로 식 염 수를 사용 합니다.</li>
	</ol>
</li>
	<li>각 환자에 대 한 A-PRP와 위약 주사의 동등한 수를 수행 합니다.</li>
	<li>의료 인젝터 총 30 G 바늘, 10 mL 주사기를 사용 하 여 5 m m의 깊이에서 interfollicular A-PRP 주사 수행 합니다.</li>
	<li>30 일 따로따로 간격을 둔 3 개의 세션을 수행 합니다.</li>
</ol>

<ol>
	<li>Rousso, D. E., Kim, S. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+review+of+medical+and+surgical+treatment+options+for+androgenetic+alopecia.">A review of medical and surgical treatment options for androgenetic alopecia.</a> JAMA Facial Plast Surg. 16, 444-450 (2014).</li><li>Schweiger, E. S., Boychenko, O., Bernstein, R. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Update+on+the+pathogenesis,+genetics+and+medical+treatment+of+patterned+hair+loss.">Update on the pathogenesis, genetics and medical treatment of patterned hair loss.</a> J Drugs Dermatol. 9, 1412-1419 (2010).</li><li>Price, V. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lack+of+efficacy+of+finasteride+in+postmenopausal+women+with+androgenetic+alopecia.">Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.</a> J Am Acad Dermatol. 43, 768-776 (2000).</li><li>Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Steroid+5alpha-reductase+deficiency+in+man:+An+inherited+form+of+male+pseudohermaphroditism.">Steroid 5alpha-reductase deficiency in man: An inherited form of male pseudohermaphroditism.</a> Science. 186, 1213-1215 (1974).</li><li>Drake, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effects+of+finasteride+on+scalp+skin+and+serum+androgen+levels+in+men+with+androgenetic+alopecia.">The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.</a> J Am Acad Dermatol. 41, 550-554 (1999).</li><li>Van Neste, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Finasteride+increases+anagen+hair+in+men+with+androgenetic+alopecia.">Finasteride increases anagen hair in men with androgenetic alopecia.</a> Br J Dermatol. 143, 804-810 (2000).</li><li>Kaufman, K. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Finasteride+in+the+treatment+of+men+with+androgenetic+alopecia.">Finasteride in the treatment of men with androgenetic alopecia.</a> J. Am Acad Dermatol. 39, 578-589 (1998).</li><li>Afifi, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Low-level+laser+therapy+as+a+treatment+for+androgenetic+alopecia.">Low-level laser therapy as a treatment for androgenetic alopecia.</a> Lasers Surg Med. 49, 27-39 (2017).</li><li>Uebel, C. O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+role+of+platelet+plasma+growth+factors+in+male+pattern+baldness+surgery.">The role of platelet plasma growth factors in male pattern baldness surgery.</a> Plast Reconstr Surg. 118, 1458-1466 (2006).</li><li>Cervelli, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effect+of+autologous+activated+platelet+rich+plasma+(AA-PRP)+injection+on+pattern+hair+loss:+Clinical+and+histomorphometric+evaluation.">The effect of autologous activated platelet rich plasma (AA-PRP) injection on pattern hair loss: Clinical and histomorphometric evaluation.</a> BioMed Res Int. , 760709 (2014).</li><li>Gkini, M. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Study+of+platelet-rich+plasma+injections+in+the+treatment+of+androgenetic+alopecia+through+an+one-year+period.">Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period.</a> J Cutan Aesthet Surg. 7, 213-219 (2014).</li><li>Gentile, P., Garcovich, S., Bielli, A., Scioli, M. G., Orlandi, A., Cervelli, V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+effect+of+platelet-rich+plasma+in+hair+regrowth:+A+randomized+placebo-controlled+trial.">The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial.</a> Stem Cells Transl Med. 4, 1317-1323 (2015).</li><li>Gentile, P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+Not-Activated+and+Activated+PRP+in+Hair+Loss+Treatment:+Role+of+Growth+Factor+and+Cytokine+Concentrations+Obtained+by+Different+Collection+Systems.">Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems.</a> Int J Mol Sci. 18 (2), 14 (2017).</li></ol>

저자는 공개 없다.

저자는 기계 및 제어 A PRP의 주사 가능한 아가 치료 옵션, 외과 의사의 손에 의해 수행 하는 수동 주입에 비해 절차 동안 통증의 감소와 함께 대표를 시연 했다. 이 프로토콜 치료 환자는 머리 수와 총 머리 밀도 수동 주사로 치료 하는 환자 보다 더 큰 증가를 발견 됐다.
머리 수와 머리 밀도의 향상을 얻기 위해 가장 중요 한 측?...

임상 비 활성화 A-PRP 주사 대상으로 머리카락의 성장을 위한 매력적인 자원 되고있다. 여기, AGA에서 A-PRP 응용 프로그램의 프로토콜은 보고, 기계 및 제어 주사를 사용 하 여. 현재, 구두만 선택적 5-α-reductase 억제제, 국 소 diaminopirimidilpiperidin-N-ossido (2.0% 및 5.0%), 그리고 낮은 수준의 레이저 치료 (LLLT) 전투 MPHL1,2 미국 식품 및 의약품 안전 청 (FDA) 승인 .
Diaminopirimidilpiperidin-N-ossido 5% 거품은 또한 FPHL에 대 한 FDA에 의해 승인 됩니다. 선택적 5-α-reductase 억제제는 주로 FPHL3, 치료에 효과가 입증 그리고, 주어진 약물의 남성 태아 외부 생식 기에 이상이 발생할 수 있습니다, 미리 폐 경기 여성4사용에 적합 하지 않습니다. 반대로, 선택 5-α-reductase 억제제의 1 밀리 그램으로 매일 치료 70% 혈 청 dihydrotestosterone (DHT) 수치를 줄이기 위해 표시 되었습니다 고 anagen 머리 머리 직경에 있는 점진적 증가 및 남성 AGA 연신 율 머리의 머리카락 성장을 촉진합니다 환자5,6, 머리 밀도에 상당한 개선을 통해. 구두 선택 5 α 환 원 효소 억제제를 사용 하 여 치료의 최대 1 년 해야 하 고 사용자 후 약물 중단된7유지 수 리비도의 상실을 개발할 수 있습니다.
최근, LLLT 사용 머리 regrowth을 자극 하 제안 되었습니다. Afifi 외. 8 LLLT 아가 대 한 효과적인 치료 여부를 결정 하는 기존 연구 결과 검토 합니다. 이식 전에 수확된 낭 활성화 헌 혈소판이 풍부한 혈장 (PRP AA)의 국 소 응용 프로그램 뿐만 아니라 전시 증가 머리 아가9, 영향을 받는 환자에서 15%로 그들의 생존 율을 증가 표시 되었습니다 이미 그 시간10동안 19% 증가 하는 터미널 머리 밀도와 밀도 3 개월 후 수술. 이러한 결과 다음 AGA 환자 1 년11에 걸쳐 칼슘 활성화 PRP로 치료 연구에서 확인 되었다.
탈모 증 치료, 및 데이터의 부족으로 임상 주사 시스템에 대 한 AA PRP12 A PRP13 의 긍정적인 결과 감안할 때,이 작품의 기본 목표는 기계적 표시 PRP 주사 프로토콜 제어.
18 남성 5 여성 환자 세 21-70 MPHL 노우 드 해밀턴 분류 규모에 의해 결정 된 대로 단계 5 단계 2에서 표시 하 고 1 단계 2 단계에서에서 FPHL로 치료 했다 루드비히 분류 규모에 의해 결정 된 대로 기계 및 A-prp 주사를 제어. AGA 진단 의료 역사, trichoscopic 분석, 부정적인 머리 풀 테스트, 실험실 검사 및 소변 검사와 임상 평가 의해 만들어졌다.
아가의 무대 노우 드 해밀턴 및 루드비히 규모를 사용 하 여 평가 되었습니다. 이 연구에 포함 된 참가자의 모든 의료에 의해 평가 했다 의사 전문 피부과 및 재생 성형 수술과 탈모 증에 두 성형 외과 의사 전문가. 저자는 모든 환자에 대 한 지역화 및 조직의 제외 기준 간주 됩니다. 체계적인 기준 혈액 및 혈소판 질환, 항 응 혈 약 그리고/또한 antiaggregation 치료, 패 혈 증, 면역 억제, 암, 이전 12 개월 동안에 구두 선택 5-α-reductase 억제제 또는 antiandrogens의 사용에 의해 대표 되었다.
지역화 된 제외 기준 이전 12 개월 동안에 국 소 치료에 대 한 diaminopirimidilpiperidin-N-ossido (2.0% 및 5.0%) 이나 코르 티 코 스테로이드의 사용에 의해 대표 되었다.

<table><tbody><tr><td>C-PunT system</td><td>Biomed Device, Modena, Italy</td><td>www.biomeddevice.it</td><td>a closed system medical device to obtain autologous concentrated platelet-rich plasma from the blood</td></tr><tr><td>Ultim Gun</td><td>Anti-Aging Medical System</td><td>www.aamedicalsystems.fr</td><td>a gun medical device to perform a mechanical and controlled injections of autologous platelet-rich plasma in a selected area of the scalp</td></tr><tr><td>Trichoscan</td><td>Tricolog GmbH, Freiburg, Germany).</td><td>www.tricholog.de</td><td>trihoScan is a digital&lt;br/&gt; software-supported epiluminescence technique for measuring hair count (number of hairs per 0.65 cm2), hair density (number of hairs per cm2), hair diameter, anagen-to-telogen ratio, and vellus&lt;br/&gt; hair-to-terminal hair ratio.</td></tr><tr><td>sodium citrate ACD-A</td><td>S.A.L.F.</td><td>SAAS2205GPO</td><td>anticoagulant for PRP preparation</td></tr><tr><td>&amp;nbsp;30-Gauge needle&amp;nbsp;</td><td>Becton Dickinson&amp;nbsp;</td><td>Z192368</td><td>needle for injections</td></tr><tr><td>10 mL mL Luer-Lock syringe</td><td>Becton Dickinson&amp;nbsp;</td><td>BD309695</td><td>syringe for PRP collection</td></tr></tbody></table>

mechanical and controlled prp injections in patients affected by androgenetic alopecia

23 환자 (18 남성과 5 여성) 21-70 세 남성 패턴 머리 손실 (MPHL) 단계 1 단계 5 노우 드 해밀턴 분류 규모에 의해 결정 되 고 여성 패턴 탈모 (FPHL)는 루드비히에 의해 결정 된 대로 단계 2 단계 1 표시 분류 규모, 비 활성화 헌 혈소판이 풍부한 혈장 (PRP A)로 치료 했다. 자가 혈액 헌 혈 (55 mL)으로 항 응고 제 시트르산 나트륨을 사용 하 여 수확 했다. A-PRP (23 mL) 수혈 서비스 프로토콜에 따라 폐쇄 시스템을 사용 하 여 모든 경우에 대 한 제작 되었습니다. 원심 (260 x g 10 분에 대 한) 다음 A-PRP 레이저 빛 선택기 장치에 삽입 했다 하 고, 원심 분리 후 A-PRP의 9 mL 수집 했다.
Androgenetic 탈모 증 (AGA)에 의해 영향을 받는 환자의 두 피 (정면, 정수 리, 정점, 및 후 두); 4 개의 지역으로 분할 되었다 취는 수행 되지 않습니다. Interfollicular A-PRP 주사 (0.2 mL x cm2) 의료 인젝터 총을 사용 하 여 5 m m의 깊이 제어 및 기계 주사에 의해 수행 되었습니다. 치료 세션 30 일 간격으로 수행 했다. 각 환자에 대 한 3 개의 치료 세션 수행 했다.
PRP는 두 피 탈모의 영향을의 안 드로 겐 관련 영역에 주입 했다. 위약 (정상적인 염 분 해결책) 다른 주사기 (10 mL)에 로드 된 하 고 비슷한 방식으로 인접 한 측에 주입.

머리 성장 매개 변수 측정 3 개월 후에 tricoscopic 분석에 의해 3 A-PRP 주사 A PRP 치료 영역 제어 영역으로 생리 식 염 수 주사를 받은 사이 기준선 측정와 비교 했다 위약입니다. 기준선에 첫 번째 치료 전에 머리 수 (122 ± 10) 통계 차이 없고 머리 밀도 (218 ± 17) 대상된 지역 및 제어 영역 (126 ± 9 기준선 머리 수 제어 영역), 사이 보고 했다 (225 ± 15 기준 머리 밀도 제어 영역)입니다.
?...

Watch this Scientific Journal Video about Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia at JoVE.com

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

이 종이 androgenetic 탈모 증 30 게이지 바늘을 갖춘 의료 인젝터 총을 사용 하 여 5 m m의 깊이에 의해 영향을 받는 23 환자의 두 피에 interfollicular 헌 혈소판이 풍부한 혈장 주사 (0.20 mL x2cm)를 설명 하는 것을 목표로 3 세션입니다.

Androgenetic 탈모 증에 의해 영향을 받는 환자에서 기계 및 제어 PRP 주사

23 patients (18 male and 5 female) aged 21-70 years who displayed male pattern hair loss (MPHL) in Stage 1 to Stage 5 as determined by the ...

mechanical-controlled-prp-injections-patients-affected-androgenetic

Universidad de Cartagena UDEC

Research

JoVE Journal

Medicine

15.0K 조회수.  University of Rome Tor Vergata. 이 종이 androgenetic 탈모 증 30 게이지 바늘을 갖춘 의료 인젝터 총을 사용 하 여 5 m m의 깊이에 의해 영향을 받는 23 환자의 두 피에 interfollicular 헌 혈소판이 풍부한 혈장 주사 (0.20 mL x2cm)를 설명 하는 것을 목표로 3 세션입니다.

비디오: Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform PrPSc 1. PrPC is detergent-soluble and sensitive to proteinase K (PK)-digestion, whereas PrPSc forms detergent-insoluble aggregates and is partially resistant to PK2-6. The conversion of PrPC to PrPSc is known to involve a conformational transition of &alpha;-helical to &beta;-sheet structures of the protein. However, the in vivo pathway is still poorly understood. A tentative endogenous PrPSc, intermediate PrP* or "silent prion", has yet to be identified in the uninfected brain7.
Using a combination of biophysical and biochemical approaches, we identified insoluble PrPC aggregates (designated iPrPC) from uninfected mammalian brains and cultured neuronal cells8, 9. Here, we describe detailed procedures of these methods, including ultracentrifugation in detergent buffer, sucrose step gradient sedimentation, size exclusion chromatography, iPrP enrichment by gene 5 protein (g5p) that specifically bind to structurally altered PrP forms10, and PK-treatment. The combination of these approaches isolates not only insoluble PrPSc and PrPC aggregates but also soluble PrPC oligomers from the normal human brain. Since the protocols described here have been used to isolate both PrPSc from infected brains and iPrPC from uninfected brains, they provide us with an opportunity to compare differences in physicochemical features, neurotoxicity, and infectivity between the two isoforms. Such a study will greatly improve our understanding of the infectious proteinaceous pathogens. The physiology and pathophysiology of iPrPC are unclear at present. Notably, in a newly-identified human prion disease termed variably protease-sensitive prionopathy, we found a new PrPSc that shares the immunoreactive behavior and fragmentation with iPrPC 11, 12. Moreover, we recently demonstrated that iPrPC is the main species that interacts with amyloid-&beta; protein in Alzheimer disease13. In the same study, these methods were used to isolate Abeta aggregates and oligomers in Alzheimer's disease13, suggesting their application to non-prion protein aggregates involved in other neurodegenerative disorders.

A new species of cellular prion protein (PrPC) has recently been identified in uninfected human brains using the methods described here. These methods can be used to isolate various PrP species, while some of them are also useful in isolating other misfolded protein aggregates from human brains.

보통 인간의 뇌에 용해와 불용성 PRP의 Oligomers의 절연

The central event in the pathogenesis of prion diseases involves a conversion of the host-encoded cellular prion protein PrPC into its pathogenic isoform ...

연구

의학

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Implant-associated infection is becoming more and more challenging to the healthcare industry worldwide due to increasing antibiotic resistance, transmission of antibiotic resistant bacteria between animals and humans, and the high cost of treating infections.
In this study, we disclose a new strategy that may be effective in preventing implant-associated infection based on the potential antimicrobial properties of platelet-rich plasma (PRP). Due to its well-studied properties for promoting healing, PRP (a biological product) has been increasingly used for clinical applications including orthopaedic surgeries, periodontal and oral surgeries, maxillofacial surgeries, plastic surgeries, sports medicine, etc.
PRP could be an advanced alternative to conventional antibiotic treatments in preventing implant-associated infections. The use of PRP may be advantageous compared to conventional antibiotic treatments since PRP is less likely to induce antibiotic resistance and PRP's antimicrobial and healing-promoting properties may have a synergistic effect on infection prevention. It is well known that pathogens and human cells are racing for implant surfaces, and PRP's properties of promoting healing could improve human cell attachment thereby reducing the odds for infection. In addition, PRP is inherently biocompatible, and safe and free from the risk of transmissible diseases.
For our study, we have selected several clinical bacterial strains that are commonly found in orthopaedic infections and examined whether PRP has in vitro antimicrobial properties against these bacteria. We have prepared PRP using a twice centrifugation approach which allows the same platelet concentration to be obtained for all samples. We have achieved consistent antimicrobial findings and found that PRP has strong in vitro antimicrobial properties against bacteria like methicillin-sensitive and methicillin-resistant Staphylococcus aureus, Group A Streptococcus, and Neisseria gonorrhoeae. Therefore, the use of PRP may have the potential to prevent infection and to reduce the need for costly post-operative treatment of implant-associated infections.

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Implant-associated infection is a significant clinical complication. This study describes an approach using platelet-rich plasma (PRP) to prevent implant-associated infections, presents the protocol for preparing PRP with constant platelet concentration, and reports the newly identified antimicrobial properties of PRP and related protocols for examining such antimicrobial properties in vitro.

준비를 한 다음 감염을 방지하기 위해 새로운 접근 방식으로 PRP<em&gt; 체외에서</emPRP의&gt; 항균 속성

Implant-associated infection is becoming more and more challenging to the healthcare industry worldwide due to increasing antibiotic resistance, ...

면역학 및 감염병학

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Autologous platelet concentrates represent promising innovative tools in the field of regenerative medicine and have been extensively used in oral surgery. Unlike platelet rich plasma (PRP) that is a gel or a suspension, Leukocyte-Platelet Rich Fibrin (L-PRF) is a solid 3D fibrin membrane generated chair-side from whole blood containing no anti-coagulant. The membrane has a dense three dimensional fibrin matrix with enriched platelets and abundant growth factors. L-PRF is a popular adjunct in surgeries because of its superior handling characteristics as well as its suturability to the wound bed. The goal of the study is to demonstrate generation as well as provide detailed characterization of relevant properties of L-PRF that underlie its clinical success.

Leucocyte-Platelet Rich Fibrin (L-PRF) represents an FDA cleared preparation of autologous platelet concentrates that possesses unique fibrin architecture, enriched platelets and abundant growth factors. Here, we present a protocol for chair-side generation of L-PRF as well as evaluate its mechanical properties including uniaxial testing and suture retention strength testing.

백혈구 - 혈소판 풍부한 섬유소, 소설 생체 재료의 특성

Autologous platelet concentrates represent promising innovative tools in the field of regenerative medicine and have been extensively used in oral ...

생체공학

Preparing Activated Platelet-Rich Plasma for Culturing Human Adipose-Derived Stem Cells

Activated platelet-rich plasma (PRP) prepared from whole blood via centrifugation demonstrated a proliferation-stimulating effect in several kinds of cultured cells, implying a possible use in regenerative medicine. Here, a double-spin method was used to prepare PRP from whole blood. PRP was further activated by autologous thrombin. The platelet count was measured in the activated PRP and the proliferation-stimulating effect in human adipose-derived stem cells (hASCs) was examined. The resulting platelet count was 11.5-times higher in PRP than in whole blood plasma. The proliferation of hASCs was markedly enhanced by incubation with 1% PRP. The described method can be used to reproducibly prepare PRP with a high concentration of platelets. PRP prepared by this method markedly promotes proliferation of hASCs.

In this report, we describe a double-spin method for preparing activated platelet-rich plasma (PRP). Using autologous thrombin, human adipose-derived stem cells (hASCs) were cultured. Activated PRP was shown to promote proliferation of hASCs.

Activated platelet-rich plasma (PRP) prepared from whole blood via centrifugation demonstrated a proliferation-stimulating effect in several kinds of ...

발생학

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

There is currently great clinical interest in the use of autologous fibroblasts for skin repair. In most cases, culture of skin cells in vitro is required. However, cell culture using xenogenic or allogenic culture media has some disadvantages (i.e., risk of infectious agent transmission or slow cell expansion). Here, an autologous culture system is developed for the expansion of human skin fibroblast cells in vitro using a patient&#8217;s own platelet-rich plasma (PRP). Human dermal fibroblasts are isolated from the patient while undergoing abdominoplasty. Cultures are followed for up to 7 days using a medium supplemented with either fetal bovine serum (FBS) or PRP. Blood cell content in PRP preparations, proliferation, and fibroblast differentiation are assessed. This protocol describes the method for obtaining a standardized, non-activated preparation of PRP using a dedicated medical device. The preparation requires only a medical device (CuteCell-PRP) and centrifuge. This device is suitable under sufficient medical practice conditions and is a one-step, apyrogenic, and sterile closed system that requires a single, soft spin centrifugation of 1,500 x g for 5 min. After centrifugation, the blood components are separated, and the platelet-rich plasma is easily collected. This device allows a quick, consistent, and standardized preparation of PRP that can be used as a cell culture supplement for in vitro expansion of human cells. The PRP obtained here contains a 1.5-fold platelet concentration compared to whole blood together, with a preferential removal of red and white blood cells. It is shown that PRP presents a boosting effect in cell proliferation compared to FBS (7.7x) and that fibroblasts are activated upon PRP treatment.

This protocol presents a device that produces PRP to boost the in vitro expansion of cells in a 100% autologous fibroblast culture system.

In Vitro 인간 섬유아세포 확장을 촉진하기 위한 자가 혈소판 풍부 혈장 생산

There is currently great clinical interest in the use of autologous fibroblasts for skin repair. In most cases, culture of skin cells in vitro is ...

Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a lesion in the Achilles tendon; prepare PRP and inject it (or the saline solution); remove the tendon; and perform biomechanical, molecular, and histological evaluations. At each step, all the procedures and methods are described in detail, so they can be reproduced easily.
Achilles tendons have been surgically sectioned (removal of a 5-mm long section). Afterwards, PRP or saline solution was injected to study whether PRP has a positive effect on the healing of the tendon. Three groups of 40 animals (a total of 120 rats were used in this study) were subdivided into 2 subgroups: PRP injection group and a saline injection control group. Rats were sacrificed at increasing time points (Group A: 5 days; Group B: 15 days; Group C: 30 days) and tendons were removed. 90 tendons underwent biomechanical testing before performing transcriptomic analysis and the 30 remaining tendons were submitted to histological analysis.

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This protocol describes the evaluation process of healing tendons in rats that have been injected with allogeneic platelet rich plasma (PRP) or saline solution after removing part of the Achilles tendon. The progress of tendon healing is evaluated at several time points using different types of analyses.

쥐의 Sectioned 아 킬 레 스 힘 줄의 치유 과정에서 수용자 혈소판이 풍부한 혈장 (PRP)의 효과: 방법론 설명

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a ...

Preparation, Procedures and Evaluation of Platelet-Rich Plasma Injection in the Treatment of Knee Osteoarthritis

Knee osteoarthritis (KOA) is one of the most frequently encountered diseases in the orthopedic department. Existing non-surgical treatments have a limited effect on the repair of cartilage and on bone regeneration. Platelet-rich plasma (PRP) is an autologous bioactive substance that can repair cartilage injury and accelerate bone regeneration effectively. However, reporting of PRP preparation protocols in clinical studies is highly inconsistent, with the majority of studies providing insufficient information to allow the protocol to be reproduced. We describe a repeatable method of preparing PRP visually, the treatment of KOA using PRP intra-articular injection, and methods of evaluating the outcome. PRP was prepared using manual double centrifugation. The PRP layer was extracted from peripheral blood and used for knee joint cavity injection. Evaluations included assessments of blood platelet concentrations and clinical outcomes. Preparation of PRP by manual centrifugation requires less apparatus and is less costly than plasma filtration or centrifugation using equipment. The centrifugation time of our double centrifugation method was 6 and 5 minutes for the respective centrifugations at forces of 800 and 1400 x g, respectively, to allow for the consistent preparation of standardized PRP. However, a manual method is susceptible to operator error, and PRP batch preparation is not available. Intra-articular injection of PRP proved to be an effective treatment for knee osteoarthritis. The entire treatment procedure took less than 30 minutes, the blood platelet concentration of PRP could be standardized, and treatment was proven to be effective when evaluated by follow-up.

Knee osteoarthritis is frequently seen in the orthopedic department. We introduce in detail the entire knee osteoarthritis treatment process with platelet-rich plasma injection, including preparation, procedures, and evaluation.

준비, 절차 및 무릎 관절염의 치료에 혈소판이 풍부한 혈장 주입의 평가

Knee osteoarthritis (KOA) is one of the most frequently encountered diseases in the orthopedic department. Existing non-surgical treatments have a limited ...

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Alopecia is a common form of hair loss which can occur in many different conditions, including male-pattern hair loss, polycystic ovarian syndrome, and alopecia areata. Alopecia can also occur as a side effect of chemotherapy in cancer patients. In this study, our goal was to develop a consistent and reliable method to quantify hair loss in mice, which will allow investigators to accurately assess and compare new therapeutic approaches for these various forms of alopecia. The method utilizes a standard gel imager to obtain and process images of mice, measuring the light absorption, which occurs in rough proportion to the amount of black (or gray) hair on the mouse. Data that has been quantified in this fashion can then be analyzed using standard statistical techniques (i.e., ANOVA, T-test). This methodology was tested in mouse models of chemotherapy-induced alopecia, alopecia areata and alopecia from waxing. In this report, the detailed protocol is presented for performing these measurements, including validation data from C57BL/6 and C3H/HeJ strains of mice. This new technique offers a number of advantages, including relative simplicity of application, reliance on equipment which is readily available in most research laboratories, and applying an objective, quantitative assessment which is more robust than subjective evaluations. Improvements in quantification of hair growth in mice will improve study of alopecia models and facilitate evaluation of promising new therapies in preclinical studies.

Alopecia is a common form of hair loss which can occur in many different conditions, including as a side-effect of chemotherapy. We have developed a method to quantify hair loss in mice, utilizing a standard gel imager to perform a grayscale analysis, to facilitate study of promising new alopecia therapies.

그레이 스케일 분석을 사용하여 마우스의 탈모의 정량 분석​​을위한 새로운 기술

Alopecia is a common form of hair loss which can occur in many different conditions, including male-pattern hair loss, polycystic ovarian syndrome, and ...

생물학

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Various ocular surface diseases are treated with blood-derived eye drops. Their use has been introduced in clinical practice because of their metabolite and growth factor content, which promotes eye surface regeneration. Blood-based eye drops can be prepared from different sources (i.e., whole blood or platelet apheresis donation), as well as with different protocols (e.g., different dilutions and freeze/thaw cycles). This variability hampers the standardization of clinical protocols and, consequently, the evaluation of their clinical efficacy. Detailing and sharing the methodological procedures may contribute to defining common guidelines. Over the last years, allogenic products have been diffusing as an alternative to the autologous treatments since they guarantee higher efficacy standards; among them, the platelet-rich plasma lysate (PRP-L) eye drops are prepared with simple manufacturing procedures. In the transfusion medicine unit at AUSL-IRCCS di Reggio Emilia, Italy, PRP-L is obtained from platelet-apheresis donation. This product is initially diluted to 0.3 x 109 platelets/mL (starting from an average concentration of 1 x 109 platelets/mL) in 0.9% NaCl. Diluted platelets are frozen/thawed and, subsequently, centrifuged to eliminate debris. The final volume is split into 1.45 mL aliquots and stored at &#8722;80 &#176;C. Before being dispensed to patients, eye drops are tested for sterility. Patients may store platelet lysates at &#8722;15 &#176;C for up to 1 month. The growth factor composition is also assessed from randomly selected aliquots, and the mean values are reported here.

Platelet lysates represent an emerging tool for the treatment of ocular surface diseases. Here, we propose a method for the preparation, dispensation, storage, and characterization of platelet lysate collected from platelet donors.

눈 표면 질환 치료를 위한 혈소판이 풍부한 혈장 용해물

Various ocular surface diseases are treated with blood-derived eye drops. Their use has been introduced in clinical practice because of their metabolite ...

A Platelet-Rich Plasma Injection into the Sectioned Achilles Tendon of a Rat

Source: Greimers, L., et al. <a href="https://appjove.unicartagenaproxy.elogim.com/v/55759">Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description.</a> J. Vis. Exp. (2018).
This video demonstrates a technique for injecting platelet-rich plasma (PRP) into the sectioned Achilles tendon of rats. A small segment is excised from the Achilles tendon of a recipient rat, the site is sutured, and the rat is allowed to recover. Concurrently, whole blood is collected from a donor rat and centrifuged to obtain PRP, which is then activated and injected into the sutured site of the recipient rat to induce tendon repair.

쥐의 절편화된 아킬레스건에 혈소판이 풍부한 혈장 주입

All procedures involving animal models have been reviewed by the local institutional animal care committee and the JoVE veterinary review board.
1. Animal ...

Androgenetic 탈모 증에 의해 영향을 받는 환자에서 기계 및 제어 PRP 주사

요약

더 많은 비디오 탐색

이 비디오의 챕터

보통 인간의 뇌에 용해와 불용성 PRP의 Oligomers의 절연

준비를 한 다음 감염을 방지하기 위해 새로운 접근 방식으로 PRP

백혈구 - 혈소판 풍부한 섬유소, 소설 생체 재료의 특성

Preparing Activated Platelet-Rich Plasma for Culturing Human Adipose-Derived Stem Cells

In Vitro 인간 섬유아세포 확장을 촉진하기 위한 자가 혈소판 풍부 혈장 생산

쥐의 Sectioned 아 킬 레 스 힘 줄의 치유 과정에서 수용자 혈소판이 풍부한 혈장 (PRP)의 효과: 방법론 설명

준비, 절차 및 무릎 관절염의 치료에 혈소판이 풍부한 혈장 주입의 평가

그레이 스케일 분석을 사용하여 마우스의 탈모의 정량 분석을위한 새로운 기술

눈 표면 질환 치료를 위한 혈소판이 풍부한 혈장 용해물

쥐의 절편화된 아킬레스건에 혈소판이 풍부한 혈장 주입

Androgenetic 탈모 증에 의해 영향을 받는 환자에서 기계 및 제어 PRP 주사

요약

더 많은 비디오 탐색

이 비디오의 챕터

보통 인간의 뇌에 용해와 불용성 PRP의 Oligomers의 절연

준비를 한 다음 감염을 방지하기 위해 새로운 접근 방식으로 PRP

백혈구 - 혈소판 풍부한 섬유소, 소설 생체 재료의 특성

Preparing Activated Platelet-Rich Plasma for Culturing Human Adipose-Derived Stem Cells

In Vitro 인간 섬유아세포 확장을 촉진하기 위한 자가 혈소판 풍부 혈장 생산

쥐의 Sectioned 아 킬 레 스 힘 줄의 치유 과정에서 수용자 혈소판이 풍부한 혈장 (PRP)의 효과: 방법론 설명

준비, 절차 및 무릎 관절염의 치료에 혈소판이 풍부한 혈장 주입의 평가

그레이 스케일 분석을 사용하여 마우스의 탈모의 정량 분석​​을위한 새로운 기술

눈 표면 질환 치료를 위한 혈소판이 풍부한 혈장 용해물

쥐의 절편화된 아킬레스건에 혈소판이 풍부한 혈장 주입

그레이 스케일 분석을 사용하여 마우스의 탈모의 정량 분석을위한 새로운 기술